Atherosclerotic Cardiovascular Disease
Conditions
Keywords
Proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibody (Anti-PCSK9), Microvascular coronary dysfunction (CMVD), Coronary angioplasty, Cardiovascular imaging
Brief summary
Proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies (anti-PCSK9) significantly reduce the serum LDL-C level, leading to a regression of the coronary epicardial plaque demonstrated by intracoronary ultrasonography (IVUS), as well as cardiovascular events (CV) in patients with atherosclerotic CV disease treated with statin. The impact of PCSK9 inhibition on coronary microcirculation has never been assessed. However, microvascular coronary dysfunction (CMVD) is a powerful prognostic marker, irrespective of conventional CV risk factors, but also of the severity of the epicardial coronary involvement detected during coronary angiography. The investigators hypothesized that anti-PCSK9 would decrease CMVD, measured by the microcirculatory resistance index (MRI) during coronary angioplasty (Percutaneous coronary intervention, PCI) in patients with myocardial ischemia proved in myocardial scintigraphy.
Interventions
3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
Sponsors
University Hospital, Grenoble
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patient, aged 40 to 85, * More than 50 kilograms * Defined at high cardiovascular risk according to European guidelines * LDL-C level ≥ 0.7 g / L (biological assessment of less than 6 months) * Having benefited from myocardial scintigraphy * For which coronarography is indicated according to European guidelines * Affiliated with social security, * Signed informed consent form
Exclusion criteria
* Clinical presentation of unstable angina * Patient whose state of physical or psychological health could compromise the obtaining of his informed consent and his compliance with the requirements of the protocol, with the study evaluation, procedures or completion. * End stage disease (estimated survival of less than one year) * Severe renal dysfunction, defined as an estimated creatinine clearance (MDRD) \< 30 mL/min at screening * Contra-indication to adenosin : hypersensitivity to active active substance or to any of the excipients, type II or III atrioventricular block or atrial disease (except for pacemaker users), long QT syndrome, severe arterial hypotension, acute heart failure, asthma and severe chronic obstructive pulmonary disease, unstable angina unstabilized by drug therapy, taking dipyridamole, aminophylline, theophylline or other xanthine base within 24 hours prior to adenosine administration * Contra-indication to heparin: hypersensitivity to active substance or to any of the excipients, past heparin induced thrombopenia type II, haemorrhage. * Prior Coronary Artery Bypass Graft Surgery (CABG) * Prior myocardial infarction in the territory of ischemia * New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \< 30% * Known hemorrhagic stroke at any time * Uncontrolled or recurrent ventricular tachycardia * Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) \> 180 mmHg or diastolic BP (DBP) \> 110 mmHg * Actual use of PCSK9 inhibitor (evolocumab or others) * Untreated or inadequately treated hyperthyroidism or hypothyroidism, controlled by biological assessment if needed, defined by thyroid stimulating hormone (TSH) \< lower limit of normal (LLN) or \> 1.5 times the upper limit of normal (ULN), respectively, and free thyroxine (T4) levels that are outside normal range at screening * Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the ULN at screening * Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal) * Personal or family history of hereditary muscular disorders * LDL apheresis within 12 months prior to randomization * Creatinine Phosphokinase (CPK) \> 5 ULN at screening * Active infection or others active disease judge by investigator incompatible with the protocol completion * Main known active infection including positive viral serology (Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus) * Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 10 years * Known sensitivity to evolocumab or their excipients to be administered during dosing or natural rubber / latex * Patient likely to not be available to complete all protocol-required study visits or procedures. * Patient in exclusion period of another study * Woman able to procreate in the absence of highly effective contraception * Persons referred to in Articles L1121-6 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Impact of a PCSK9 inhibitor treatment on coronary microvascular dysfunction (CMVD) at 4 weeks in patients with atherosclerotic cardiovascular disease. | 4 weeks | Index of microcirculatory resistance (IMR), measured during invasive coronary angiography and expressed in mmHg.s |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of a PCSK9 inhibitor treatment on soluble VE-cadherin rate (sVE). | 4 weeks | Measurement of sVE rate at baseline and four weeks after treatment with evolocumab or without treatment. |
| Impact of a PCSK9 inhibitor treatment on brachial hyperemia (HB). | 4 weeks | Variation of the luminal diameter of the humeral artery with baseline and four weeks after treatment with evolocumab or without treatment. |
| Impact of a PCSK9 inhibitor treatment on the rate of peri-procedural myocardial infarction. | 4 weeks | Troponin I level after PCI (peri-procedural myocardial pain will be defined as a post-angioplasty troponin level 10 times higher than the 99th percentile of troponin I). |
| Correlations between invasive and non-invasive (myocardial scintigraphy - myocardial perfusion entropy (MPE), concentration of sVE, HB) measurements of coronary microvascular dysfunction. | 4 weeks | IMR, MPE, sVE and the variation of the luminal diameter of the humeral artery. |
| Correlations between the cardiovascular risk and the concentration of sVE and MPE. | 4 weeks | Risk score, sVE rate and MPE. |
Countries
France
Contacts
Primary ContactGilles Barone-Rochette, MD, PhD
Backup ContactClémence Charlon
Outcome results
None listed